Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy

被引:38
|
作者
Sainz-Esteban, Aurora [3 ]
Prasad, Vikas [1 ,2 ]
Schuchardt, Christiane [1 ,2 ]
Zachert, Carolin [1 ,2 ]
Manuel Carril, Jose [3 ]
Baum, Richard P. [1 ,2 ]
机构
[1] Zent Klin Bad Berka, Dept Nucl Med, D-99437 Bad Berka, Germany
[2] Zent Klin Bad Berka, Ctr PET CT, D-99437 Bad Berka, Germany
[3] Hosp Univ Marques de Valdecilla, Dept Nucl Med, Santander, Spain
关键词
Lu-177-DOTA-TATE; Dosimetry scan; Ga-68-DOTA-TATE; Neuroendocrine tumour; RADIOLABELED SOMATOSTATIN ANALOG; TYR(3) OCTREOTATE; BIODISTRIBUTION; SCINTIGRAPHY; AFFINITY; GA-68;
D O I
10.1007/s00259-011-2003-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose The aim of the study was to compare sequential Lu-177-DOTA-TATE planar scans (Lu-177-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic Ga-68-DOTA-TATE positron emission tomography (PET)/CT (Ga-68-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods. Methods A total of 44 patients (59 +/- 11 years old) with biopsy-proven NET underwent Ga-68-DOTA-TATE and Lu-177-DOTA-TATE imaging within 7.9 +/- 7.5 days between the two examinations. Lu-177-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on Lu-177-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on Ga-68-DOTA-TATE studies obtained before PRRT. Results A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were Ga-68-DOTA-TATE positive and Lu-177-DOTA-TATE negative, whereas 9 were Ga-68-DOTA-TATE negative and Lu-177-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for Lu-177-DOTA-TATE as compared to Ga-68-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h) Lu-177-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (n=77; mean size 3.8 cm) were significantly larger than discordant lesions (n=38; mean size 1.6 cm) (p<0.05). No such significance was found for differences in maximum standardized uptake value (SUVmax). However, concordant liver lesions with a score from 1 to 3 in the 72-h (177)LuDOTA- TATE scan had a lower SUVmax (n=23; mean 10.9) than those metastases with a score of 4 (n=97; mean SUVmax 18) (p<0.05). Conclusion Although Lu-177-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for thedetection of metastases, they failed to pick up 9% of lesions seen on the Ga-68-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 50 条
  • [1] Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy
    Aurora Sainz-Esteban
    Vikas Prasad
    Christiane Schuchardt
    Carolin Zachert
    José Manuel Carril
    Richard P. Baum
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 501 - 511
  • [2] Comparison of Lu-177 DOTA-TATE sequential planar dosimetry scans with Ga-68 DOTA-TATE PET/CT images in patients with neuroendocrine tumours
    Sainz Esteban, A.
    Prasad, V.
    Carril Carril, J. M.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S231 - S232
  • [3] Use of 68Ga-DOTA-TATE PET/CT for predicting the dose of 177Lu-DOTA-TATE therapy in patients with neuroendocrine tumors (NETs)
    Scheler, Simone
    Fischer, Richard
    Fani, Melpomeni
    Maecke, Helmut
    Weber, Wolfgang
    Wild, Damian
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [4] Simultaneous Imaging of 68Ga-DOTA-TATE and 177Lu-DOTA-TATE in Murine Models of Neuroblastoma
    Zheng, Yifan
    Huh, Yoonsuk
    Vetter, Kai
    Nasholm, Nicole
    Gustafson, Clay
    Seo, Youngho
    IEEE TRANSACTIONS ON RADIATION AND PLASMA MEDICAL SCIENCES, 2023, 7 (01) : 75 - 82
  • [5] Morphologic and metabolic response assessment of 177Lu-DOTA-TATE peptide receptor radionuclide therapy (PRRT) with 68Ga-DOTA-TOC PET/CT
    Gaertner, F. C.
    Hillerer, C.
    Lapa, C.
    Miederer, M.
    D'Alessandria, C.
    Wester, H.
    Schwaiger, M.
    Scheidhauer, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S267 - S267
  • [6] 177Lu-DOTA-TATE in Peptide Receptor Radionuclide Therapy: first year experience in Turkey
    Kabasakal, L.
    Demirci, E.
    Ocak, M.
    Decristoforo, C.
    Papilla, C.
    Araman, A.
    Uslu, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S428 - S428
  • [7] 177Lu-DOTA-TATE Therapy in Midgut Neuroendocrine Tumours: Experience of a Tertiary Center
    Marques, B.
    Paredes, S.
    Pereira, C. A.
    Ferreira, G.
    Costa, C.
    Santos, A. P.
    Torres, I
    Sanches, C.
    Giesteira, L.
    Azevedo, I
    Duarte, H.
    Lucena Sampaio, I
    NEUROENDOCRINOLOGY, 2019, 108 : 222 - 222
  • [8] Intraindividual comparison of SUVmax, SUVmean and tumor volume results with 177Lu-DOTA-TATE SPECT/CT and 68Ga-DOTA-TOC PET/CT in neuroendocrine tumor patients
    Rodrigues, M.
    Thorstensen, E.
    Uprimny, C.
    Kendler, D.
    Virgolini, I.
    Warwitz, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S326 - S326
  • [9] Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE
    Prado-Wohlwend, S.
    Bernal-Vergara, J. C.
    Utrera-Costero, A.
    Canon-Sanchez, J. R.
    Agudelo-Cifuentes, M.
    Bello-Arques, P.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (01): : 55 - 65
  • [10] Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTA-TATE PET/CT in patients with metastatic neuroendocrine tumors: a preliminary study
    Zhu, Wenjia
    Bai, Chunmei
    Zhao, Hong
    Yao, Shaobo
    Huo, Li
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60